Evidence map›Paper›PMID 42210914›Full record

ArticleKidney international reports2026

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.

Michelle N Rheault, Katherine M Dell, Kenneth V Lieberman, Kevin Meyers, Ana Paredes, Edward Murphy, Jula K Inrig, Radko Komers, Howard Trachtman

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03493685 (A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03493685 phase3completednot on this map

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS

TypeinterventionalSponsorTravere Therapeutics, Inc.Ran2018 to 2026Enrolled371ConditionsFocal Segmental GlomerulosclerosisArmssparsentan, Irbesartan
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michelle N RheaultDivision of Pediatric Nephrology, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Katherine M DellCenter for Pediatric Nephrology and Hypertension, Cleveland Clinic Children's and Case Western Reserve University, Cleveland, Ohio, USA.
Kenneth V LiebermanDepartment of Pediatric Nephrology, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Kevin MeyersDivision of Nephrology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, USA.
Ana ParedesNiklaus Children's Hospital, Miami, Florida, USA.
Edward MurphyTravere Therapeutics, Inc., San Diego, California, USA.
Jula K InrigTravere Therapeutics, Inc., San Diego, California, USA.
Radko KomersTravere Therapeutics, Inc., San Diego, California, USA.
Howard TrachtmanDivision of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sparsentan, a nonimmunosuppressive dual endothelin angiotensin receptor antagonist, led to rapid and sustained proteinuria reductions versus maximum labeled dose irbesartan in patients with focal segmental glomerulosclerosis (FSGS) in the phase 3 DUPLEX trial (NCT03493685). Here, we describe the efficacy and safety of sparsentan in the pediatric patients enrolled in DUPLEX. Methods: DUPLEX was a 108-week randomized trial of sparsentan versus irbesartan (active control) in patients with FSGS (excluding known secondary causes). A Results: Thirty-five pediatric patients received sparsentan ( Conclusion: In this

Indexed as

clinical trialfocal segmental glomerulosclerosispediatricproteinuriasparsentantherapy

Identifiers

PMID42210914
PMCPMC13213750

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.